Novel Formulations of Pharmacological Agents, Methods for the Preparation Thereof and Methods for the Use Thereof.

Details for Australian Patent Application No. 2002300723 (hide)

International Classifications

Event Publications

20 February 2003 Application Open to Public Inspection

Published as AU-B-2002300723

20 January 2005 Application Accepted

Published as AU-B-2002300723

19 May 2005 Standard Patent Sealed

11 December 2008 Alteration of Name

The name of the patentee has been altered to Abraxis BioScience, LLC

30 April 2009 Extension of Term of Standard Patents

Abraxis BioScience, LLC The earliest first regulatory approval date provided by the patentee 17 Oct 2008 For the goods ABRAXANE Nanoparticle albumin-bound paclitaxel

11 June 2009 Extension of Term of Standard Patents

Abraxis BioScience, LLC The earliest first regulatory approval date provided by the patentee 17 Oct 2008 For the goods ABRAXANE nanoparticle albumin-bound paclitaxel Address for service in Australia: Spruson & Ferguson Level 35 St Extensions of Term of Standard Patents Extension of Term of a Standard Patent relating to Pharmaceutical Substances Applications Accepted Martins Tower 31 Market Street Sydney NSW 2000

24 December 2009 Extension granted

Abraxis BioScience, LLC The earliest first regulatory approval date provided by the patentee 17 Oct 2008 For the goods ABRAXANE nanoparticle albumin-bound paclitaxel Extension of Term of patent pursuant to Section 77 expires on 26 Jun 2023

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.